При проучвания фаза 2/ 3, поради влошаване на белодробната функция от проучванията са били не
In Phase 2/ 3 trials, 9 out of 2498 subjects treated with EXUBERA were discontinued from trials due to a decline in pulmonary function whose end of study FEV1 showed a decline of ≥ 15% from baseline.